Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 10/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 10/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.56 |
| ▸ | CHRNB3 | Q05901 | 5/20 | 0.56 |
| ▸ | CHRNA6 | Q15825 | 5/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.54 |
| ▸ | HSD11B2 | P80365 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4696770 | 0.91 | HSD11B1 (0.69) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL3283711 | 0.84 | HPGD (0.56) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL700843 | 0.79 | HPGD (0.83) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL700845 | 0.79 | HPGD (0.83) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL3282290 | 0.78 | HPGD (0.60) | HPGDCHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL1793319 | 0.78 | HPGD (0.54) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL26649932 | 0.78 | RIPK1 (0.40) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL24706079 | 0.77 | CHRNB2 (0.58) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL2946268 | 0.76 | HPGD (0.78) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 | |
| SCHEMBL2946264 | 0.76 | HPGD (0.78) | HPGDCHRNB2CHRNA3CHRNA4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1761542-B1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | claimed |
| CN-101001860-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2007-07-18 | — | — | CN | claimed |
| EP-1761542-A2 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005121145-A2 | OCTAHYDRO-PYRROLO[3,4-C] DERIVATIVES AND THEIR USE AS ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | WO | claimed |
| CN-115151252-B | Iron death inhibitor-diarylamine acetamides | 维泰瑞隆有限公司 | 2024-08-27 | — | — | CN | disclosed |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | Sironax Ltd. (KY) | 2023-05-25 | — | — | US | disclosed |
| CN-115151252-A | Iron death inhibitors diarylamine para-acetamides | 维泰瑞隆有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-7714018-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-05-11 | — | — | US | disclosed |
| EP-1761542-B1 | OCTAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AN THEIR USE AS ANTIVIRAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-01-02 | — | — | EP | disclosed |
| CN-101001860-A | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (CH) | 2007-07-18 | — | — | CN | disclosed |
| US-20070117859-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2007-05-24 | — | — | US | disclosed |
| US-7164019-B2 | Such as cyclopentanecarboxylic acid {(S)-1-phenyl-3-[5-(pyridine-3-carbonyl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-propyl}-amide; antagonists of chemokine receptors, useful for treating/preventing human immunodeficiency virus infection, AIDS or ARC | ROCHE PALO ALTO LLC (US) | 2007-01-16 | — | — | US | disclosed |
| US-20060014767-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014767-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | HPGD 559/4885CHRNB2 2902/4885CHRNA3 1232/4885 |
| US-20230159492-A1 | FERROPTOSIS INHIBITORS - DIARYLAMINE PARA-ACETAMIDES | AIFM2, FECH, GPX4 | HPGD 522/4885CHRNB2 4824/4885CHRNA3 4851/4885 |
| US-20070117859-A1 | Heterocyclic antiviral compounds | CCR5, ACKR3, CXCR1 | HPGD 559/4885CHRNB2 2902/4885CHRNA3 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.